We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Crystallics - a New Company with a Long History in Pharmaceutical Development

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Crystallics - a New Company with a Long History in Pharmaceutical Development"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Avantium Pharma BV, has been spun out from Avantium Holding BV in a management buy-out to create Crystallics.

The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract manufacturing organizations and agrochemical companies.

Gunnar Staaf, Chief Executive Officer, commented: “Crystallics’ core business focus will be in solid state research and pre-formulation, an area where we have built up considerable expertise over the last decade. I believe our proprietary technology, experienced team, together with a strong customer focus, make Crystallics an ideal partner.”

Solid state research plays a central role in the pharmaceutical industry. Active pharmaceutical ingredients can exist in a number of solid forms, such as polymorphs, salts, co-crystals, hydrates, or amorphous forms.

Various solid state forms of the same active pharmaceutical ingredient will have different characteristics that can have a significant impact on the safety and efficacy of a drug product.

Marcel Hoffmann, Chief Scientific Officer, said: “We believe in a tailored, science based approach to meet the customer’s project objectives and budgets. Quality and speed will be at the heart of our research approach.”